NCT06708455 - Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 15, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

September 30, 2028

Conditions

Malignant Melanoma With MetastasisMalignant MelanomaMalignant Melanoma Stage IIIcMalignant Melanoma Stage IV

Interventions

BIOLOGICAL

RAPA-201 Rapamycin Resistant T Cells

Autologous Rapamycin-Resistant Th1/Tc1 Cells

DRUG

Chemotherapy Prior to RAPA-201 Therapy

Carboplatin + Paclitaxel Regimen (CP Regimen)

Trial Locations (1)

Hackensack University Medical Center, Hackensack

All Listed Sponsors

lead

Rapa Therapeutics LLC

INDUSTRY